

An Efficient and Facile Synthesis of Quinoxaline Derivatives Catalyzed by KHSO_4 at Room Temperature

Hossein A. Oskooie*, Majid M. Heravi*, Khadijeh Bakhtiari, and Shima Taheri

Department of Chemistry, School of Sciences, Azzahra University Vanak, Tehran, Iran

Received March 31, 2007; accepted April 15, 2007; published online July 5, 2007

© Springer-Verlag 2007

Summary. A facile synthesis of quinoxaline derivatives catalyzed by KHSO_4 in very high yields at room temperature is reported.

Keywords. 1,2-Diketones; *o*-Phenylenediamines; KHSO_4 ; Quinoxaline derivatives.

Introduction

The synthesis of quinoxaline derivatives has been of considerable interest to chemists because of their wide range of biological and pharmaceutical properties. Quinoxaline is an important component of pharmacologically active compounds. Although rarely occurring in Nature, the synthetic quinoxaline ring is a part of various antibiotics such as Echinomycin, Levomycin, and Actinoleutin [1] that are known to inhibit growth of *Gram*-positive bacteria and are active against various transplantable tumors [2]. In addition, quinoxaline derivatives have been reported to possess significant biological activities, such as antihelmintic, anticancer [3], antimicrobial, antifungal, and antidepressant [4, 5], and have applications in dyes [6]. They are efficient electroluminescent materials [7], organic semiconductors [8], building blocks for the synthesis of anion receptors [9], cavitands [10], dehydroannulenes [11], and DNA cleaving agents [12].


Thus, the synthesis of quinoxalines currently is of great interest. Various methods have been developed

for the preparation of substituted quinoxalines [13]. To the best of our knowledge the following methods have been applied: Bi-catalysed oxidative coupling of epoxides and *ene*-1,2-diamines [14], from α -hydroxy ketones *via* a tandem oxidation process using $\text{Pd}(\text{OAc})_2$ or $\text{RuCl}_2\text{-(PPh}_3)_3\text{-TEMPO}$ [15] and MnO_2 [16], heteroannulation of nitroketene *N,S*-aryliminoacetals with POCl_3 [17], solid-phase synthesis on SynPhaseTM Lanterns [18], cyclization of α -aryl-imino oximes of α -dicarbonyl compounds under reflux in acetic anhydride [19], condensation of 1,2-dicarbonyl compounds and *o*-phenylenediamines in *MeOH/AcOH* under microwave irradiation [20], iodine catalyzed cyclocondensation of 1,2-dicarbonyl compounds and substituted *o*-phenylenediamines in *DMSO* [21] and CH_3CN [22]. However, these methods have many disadvantages, such as low yields, long reaction times, the use of toxic solvents, and harsh reaction conditions. Thus, the development of a new catalyst for the synthesis of quinoxaline derivatives would be highly desirable.

KHSO_4 is one of the components of a triple salt with the formula $2\text{KHSO}_5 \cdot \text{KHSO}_4 \cdot \text{K}_2\text{SO}_4$, the so-called Oxone, which is used as highly efficient, mild, and sole oxidizing agent in many organic reagents [23]. Synthesis of 2-arylsubstituted benzimidazoles by oxidative condensation of aldehydes with *o*-phenylenediamine in the presence of KHSO_4 has also been reported [24].

Recently, we have reported the use of KHSO_4 as an efficient catalyst for the synthesis of 1,1-dia-

* Corresponding author. E-mail: mmh1331@yahoo.com



Scheme 1

tates under solvent-free conditions [25]. Because we are interested in the synthesis of heterocyclic compounds [26], very recently, we have reported the synthesis of quinoxaline derivatives catalyzed by $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ [27a], *IBX* [27b], $\text{Zn}[\text{L-proline}]$ [28], and heteropolyacid [29]. Herein, we wish to report an efficient and facile methodology for the synthesis of quinoxalines of high purity using KHSO_4 as catalyst at room temperature.

Results and Discussion

When a mixture of benzil (**1a**, 1 mmol) and *o*-phenylenediamine (**2a**, 1 mmol) and a catalytic amount of KHSO_4 (10 mol%) in EtOH was stirred at room temperature, the mixture solidified after 15 min. At this stage, TLC analysis showed that the reactands were completely consumed and the corresponding quinoxaline **3a** was formed (Scheme 1). Upon heating the reaction mixture, the product dissolved in ethanol and the catalyst could be separated by simple filtration. The pure product **3a** (Scheme 1) was obtained (99% yield) without any further recrystallization.

The scope and the generality of the present method was then further demonstrated by condensation of various substituted *o*-phenylenediamines with 1,2-dicarbonyl compounds. The results are presented in Table 1. In general, with electron donating substituents in the amine part, high yields of products were obtained, whereas the effect is contrary with electron withdrawing substituents. On the other hand, electron donating substituents associated with aromatic 1,2-diketone decreased the product yields and the effect is contrary with electron withdrawing groups. However, the variations in the yields were very small and both substituted *o*-phenylenediamines, 4-nitro and 4-methyl, gave the condensed products in excellent yields with differently substituted 1,2-diketones.

Table 1. Synthesis of 2,3-disubstituted quinoxalines **3** catalyzed by KHSO_4

Product	R	R ¹	Time/min	Yield/% ^{a,b}	mp/°C
3a	H	H	15	99	128–129
3b	OCH ₃	H	12	97	151–152.5
3c	H	NO ₂	30	92	193–194
3d	OCH ₃	NO ₂	10	93	192–194
3e	H	CH ₃	14	99	117–118
3f	OCH ₃	CH ₃	12	98	125–127

^a Yields refer to isolated pure products

^b All products were well characterized using melting point, ¹H NMR, and IR spectra [21, 22, 27–29]

Though the role of KHSO_4 is not clear, we think that it can act as a mild *Brønsted* acid. In the absence of KHSO_4 the reaction was slow and also requires refluxing conditions providing unsatisfactory yields. We also evaluated the amount of KHSO_4 required for this transformation. As less as 5 mol% of the KHSO_4 can catalyze the reaction to the same extent, but needs a little longer reaction times (>1 h).

In conclusion, we developed a simple, clean, convenient, and efficient method for the synthesis of quinoxalines from various 1,2-diketones and *o*-phenylenediamines using KHSO_4 as catalyst under mild reaction conditions at room temperature and without any side products. Some of the major advantages of this procedure are the ambient conditions, very good yields, very short reaction times, and use of an inexpensive, green, readily available, and easily to handle catalyst, simple work-up procedure, and absence of volatile and hazardous solvents.

Experimental

All chemicals were purchased from commercial suppliers and were used as received. Melting points were measured by using the capillary tube method with an electrothermal 9200 appa-

ratus. ^1H NMR spectra were recorded on a Bruker AQS AVANCE-300 MHz spectrometer using *TMS* as an internal standard (CDCl_3 solution). IR spectra were recorded from KBr disk on the FT-IR Bruker Tensor 27. All products were well characterized by comparison with authentic samples by TLC, spectral, and physical data [21, 22, 27–29].

Preparation of Quinoxalines Catalyzed by KHSO_4 : General Procedure

A mixture of 1 mmol 1,2-diketone **1**, 1 mmol 1,2-diaminoarene **2**, and 10 mg KHSO_4 (10 mol%) in 3 cm^3 *EtOH* was stirred at room temperature. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was heated, the product dissolved in ethanol, and the catalyst was separated from the reaction mixture by simple filtration. After cooling the solvent to room temperature the pure product **3** was obtained. The structures of the synthesized products were confirmed by FT-IR and ^1H NMR spectra.

Acknowledgements

H.A.O. is grateful to Azzahra University research council for the partial financial support.

References

- [1] a) Dell A, William DH, Morris HR, Smith GA, Feeny J, Roberts GCK (1975) *J Am Chem Soc* **97**: 2497; b) Bailly C, Echepare S, Gago F, Waring M (1999) *J Anti-Cancer Drug Des* **15**: 291
- [2] Sato S, Shiratori O, Katagiri K (1967) *J Antibiot* **20**: 270 and references cited therein
- [3] Sakata G, Makino K, Kurasawa Y (1998) *Heterocycles* **27**: 2481 and references cited therein
- [4] Ali MM, Ismail MMF, El-Gabby MSA, Zahran MA, Ammar TA (2000) *Molecules* **5**: 864
- [5] Sarges R, Howard HR, Browne RC, Label LA, Seymour PA (1990) *J Med Chem* **33**: 2240
- [6] a) Brock ED, Lewis DM, Yousaf TI, Harper HH (1999) The Procter and Gamble Company, USA. WO 9951688; b) Sonawane ND, Rangnekar DW (2002) *J Heterocycl Chem* **39**: 303; c) Katoh A, Yoshida T, Ohkando J (2000) *Heterocycles* **52**: 911
- [7] Thomas KRJ, Marappan V, Jiann TL, Chang-Hao C, Yu-ai T (2005) *Chem Mater* **17**: 1860
- [8] a) Dailey S, Feast JW, Peace RJ, Saga RC, Till S, Wood EL (2001) *J Mater Chem* **11**: 2238; b) O'Brien D, Weaver MS, Lidzey DG, Bradley DDC (1996) *Appl Phys Lett* **69**: 881
- [9] Jonathan LS, Hiromitsu M, Toshihisa M, Vincent ML, Hiroyuki F (2002) *Chem Commun* 862
- [10] a) Jonathan LS, Hiromitsu M, Toshihisa M, Vincent ML, Hiroyuki F (2002) *J Am Chem Soc* **124**: 13474; b) Peter PC, Gang Z, Grace AM, Carlos H, Linda MGT (2004) *Org Lett* **6**: 333
- [11] Sascha O, Rudiger F (2004) *Synlett* 1509
- [12] Louis S, Marc MG, Jory JW, Joseph PB (2003) *J Org Chem* **68**: 4179
- [13] a) Petukhov PA, Tkachev AV (1997) *Tetrahedron* **53**: 9761; b) Kaupp G, Naimi-Jamal MR (2002) *Eur J Org Chem* 1368; c) Chen P, Barrish JC, Iwanowicz E, Lin J, Bednarz MS, Chen B-C (2001) *Tetrahedron Lett* **42**: 4293; d) Soderberg BCG, Wallace JM, Tamariz J (2002) *Org Lett* **4**: 1339; e) Suginome M, Collet S, Ito Y (2002) *Org Lett* **4**: 351; f) Mukhopadhyay R, Kundu NG (2000) *Tetrahedron Lett* **41**: 9927; g) Bunce RA, Herron DM, Ackerman ML (2000) *J Org Chem* **65**: 2847; h) Banik BK, Banik I, Hackfeld L, Becker FF (2002) *Heterocycles* **56**: 467; i) Goswami S, Adak AK (2003) *Chem Lett* **32**: 678
- [14] Antoniotti S, Donach E (2002) *Tetrahedron Lett* **43**: 3971
- [15] Robinson RS, Taylor RJK (2005) *Synlett* 1003
- [16] a) Raw SA, Wilfred CD, Taylor RJK (2004) *Org Biomol Chem* **2**: 788; b) Raw SA, Wilfred CD, Taylor RJK (2003) *Chem Commun* 2286
- [17] Venkatesh C, Singh B, Mahata PK, Ila H, Junjappa H (2005) *Org Lett* **7**: 2169
- [18] Wu Z, Ede NJ (2001) *Tetrahedron Lett* **42**: 8115
- [19] Xekoukoulotakis NP, Hadjiantonios MCP, Maroulis AJ (2000) *Tetrahedron Lett* **41**: 10299
- [20] Zhao Z, Wisnoski DD, Wolkenberg SE, Leister WH, Wang Y, Lindsley CW (2004) *Tetrahedron Lett* **45**: 4873
- [21] Bhosale RS, Sarda SR, Ardhpure SS, Jadhav WN, Bhusare SR, Pawar RP (2005) *Tetrahedron Lett* **46**: 7183
- [22] More SV, Sastry MNV, Wang C-C, Yao C-F (2005) *Tetrahedron Lett* **46**: 6345
- [23] a) Travis BR, Sivakumar M, Hollist GO, Borhan B (2003) *Org Lett* **5**: 1031; b) Bolm C, Magnus AS, Hildebrand JP (2000) *Org Lett* **2**: 1173; c) Thottumkara AP, Bowsher MS, Vinod TK (2005) *Org Lett* **7**: 2933
- [24] Ma HQ, Wang YL, Wang JY (2006) *Heterocycles* **68**: 1669
- [25] Heravi MM, Bakhtiari Kh, Taheri Sh, Oskooie HA (2005) *Green Chem* **7**: 867
- [26] a) Heravi MM, Nami N, Oskooie HA, Hekmatshoar R (2006) *Phosphorus Sulfur Silicon* **181**: 87; b) Heravi MM, Tajbakhsh M, Ahmadi AN, Mohajerani B (2006) *Monatsh Chem* **137**: 175; c) Tajbakhsh M, Mohajerani B, Heravi MM, Ahmadi AN (2005) *J Mol Catal A* **236**: 216
- [27] a) Heravi MM, Taheri SH, Bakhtiari KH, Oskooie HA (2007) *Catal Commun* **8**: 211; b) Heravi MM, Bakhtiari Kh, Tehrani MH, Javadi NM, Oskooie HA (2006) *Arkivoc* (xvi) 16
- [28] Heravi MM, Tehrani MH, Bakhtiari KH, Oskooie HA (2006) *Catal Commun* (in press)
- [29] Heravi MM, Bakhtiari KH, Bamoharram FF, Tehrani MH (2007) *Monatsh Chem*